Stela M.K. Rates

Pharmacy School Federal University of Rio Grande do Sul, Porto Alegre, Rio Grande do Sul, Brazil 
"Stela Rates"
Mean distance: 16.35
BETA: Related publications


You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.

Borsoi M, Nunes LED, Barbosa AR, et al. (2020) Intermittent repeated stress but not ketamine changes mice response to antidepressants. Neuroscience Letters. 135452
Neves G, Borsoi M, Antonio CB, et al. (2017) Is Forced Swimming Immobility a Good Endpoint for Modeling Negative Symptoms of Schizophrenia? - Study of Sub-Anesthetic Ketamine Repeated Administration Effects. Anais Da Academia Brasileira De Ciencias. 0
Betti AH, Antonio CB, Pompeu TE, et al. (2016) LASSBio-1422: a new molecular scaffold with efficacy in animal models of schizophrenia and disorders of attention and cognition. Behavioural Pharmacology
Antonio CB, Betti AH, Herzfeldt V, et al. (2016) LASSBio-579, a prototype antipsychotic drug, and clozapine are effective in novel object recognition task, a recognition memory model. Behavioural Pharmacology. 27: 339-49
Müller LG, Borsoi M, Stolz ED, et al. (2015) Diene Valepotriates from Valeriana glechomifolia Prevent Lipopolysaccharide-Induced Sickness and Depressive-Like Behavior in Mice. Evidence-Based Complementary and Alternative Medicine : Ecam. 2015: 145914
Stolz ED, Müller LG, Antonio CB, et al. (2014) Determination of pharmacological interactions of uliginosin B, a natural phloroglucinol derivative, with amitriptyline, clonidine and morphine by isobolographic analysis. Phytomedicine : International Journal of Phytotherapy and Phytopharmacology. 21: 1684-8
Pompeu TE, Alves FR, Figueiredo CD, et al. (2013) Synthesis and pharmacological evaluation of new N-phenylpiperazine derivatives designed as homologues of the antipsychotic lead compound LASSBio-579. European Journal of Medicinal Chemistry. 66: 122-34
Gomes TF, Pompeu TE, Rodrigues DA, et al. (2013) Biotransformation of LASSBio-579 and pharmacological evaluation of p-hydroxylated metabolite a N-phenylpiperazine antipsychotic lead compound. European Journal of Medicinal Chemistry. 62: 214-21
Neves G, Antonio CB, Betti AH, et al. (2013) New insights into pharmacological profile of LASSBio-579, a multi-target N-phenylpiperazine derivative active on animal models of schizophrenia. Behavioural Brain Research. 237: 86-95
Passos JJ, De Sousa FB, Mundim IM, et al. (2012) In vivo evaluation of the highly soluble oral β-cyclodextrin-Sertraline supramolecular complexes. International Journal of Pharmaceutics. 436: 478-85
See more...